Requirements for Proper Immunosuppressive Regimens to Limit Translational Failure of Cardiac Cell Therapy in Preclinical Large Animal Models

Evelyne J. Demkes, Simone Rijken, Mariusz K. Szymanski, Imo E. Hoefer, Joost P.G. Sluijter, Saskia C.A. de Jager*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Downloads (Pure)

Abstract

Various cell-based therapies are currently investigated in an attempt to tackle the high morbidity and mortality associated with heart failure. The need for these therapies to move towards the clinic is pressing. Therefore, preclinical large animal studies that use non-autologous cells are needed to evaluate their potential. However, non-autologous cells are highly immunogenic and trigger immune rejection responses resulting in potential loss of efficacy. To overcome this issue, adequate immunosuppressive regimens are of imminent importance but clear guidelines are currently lacking. In this review, we assess the immunological barriers regarding non-autologous cell transplantation and immune modulation with immunosuppressive drugs. In addition, we provide recommendations with respect to immunosuppressive regimens in preclinical cardiac cell-replacement studies.

Original languageEnglish
Pages (from-to)88-99
Number of pages12
JournalJournal of Cardiovascular Translational Research
Volume14
Issue number1
Early online date31 May 2020
DOIs
Publication statusPublished - Feb 2021

Keywords

  • Animal models
  • Cell therapy
  • Heart failure
  • Immunosuppression
  • Preclinical
  • T-cells
  • Xenogeneic

Fingerprint

Dive into the research topics of 'Requirements for Proper Immunosuppressive Regimens to Limit Translational Failure of Cardiac Cell Therapy in Preclinical Large Animal Models'. Together they form a unique fingerprint.

Cite this